QuidelOrtho Corporation
QuidelOrtho Corporation and BÜHLMANN Laboratories AG have announced the launch of two critical gastrointestinal assays: the fecal calprotectin (fCAL®) turbo and fecal pancreatic elastase (fPELA®) turbo. These assays are now available on QuidelOrtho’s VITROS Systems as a MicroTipTM Partnership Assay (MPA), enhancing diagnostic capabilities in clinical settings.
The fCAL turbo assay measures fecal calprotectin levels, which is vital for diagnosing inflammatory bowel disease (IBD) and distinguishing it from conditions such as irritable bowel syndrome. The fPELA turbo assay measures fecal pancreatic elastase, assisting healthcare providers in assessing pancreatic insufficiency. Both assays utilize particle-enhanced turbidimetric immunoassay technology, allowing for rapid and accurate testing.
Enhanced Diagnostic Tools for Healthcare Professionals
This partnership marks a significant advancement in gastrointestinal diagnostics. The availability of these assays on the VITROS Systems streamlines the testing process, providing healthcare professionals with reliable tools to evaluate gastrointestinal disorders effectively.
According to QuidelOrtho, the integration of the fCAL and fPELA assays into their existing platform will improve patient care by enabling quicker diagnosis and management of related conditions. The assays are designed to deliver results with greater precision, reducing the need for more invasive testing methods.
Healthcare providers can now perform these tests with confidence, given the rigorous validation processes employed by both QuidelOrtho and BÜHLMANN Laboratories AG. This collaboration underscores the commitment of both organizations to enhance patient outcomes through innovative diagnostic solutions.
Broader Implications for Patient Care
The introduction of the fCAL turbo and fPELA turbo assays is expected to have a considerable impact on the medical community. With an increasing prevalence of gastrointestinal disorders globally, tools that facilitate early detection and treatment are more crucial than ever.
The assays are set to play an important role in improving the quality of patient diagnosis, particularly for those experiencing symptoms related to IBD and pancreatic insufficiency. By implementing these advanced testing methods, healthcare providers can offer tailored treatment options to patients, ultimately leading to better health outcomes.
In conclusion, the collaboration between QuidelOrtho and BÜHLMANN Laboratories AG not only introduces new diagnostic tools but also reinforces the importance of innovative partnerships in the healthcare industry. The fCAL and fPELA assays represent a step forward in the fight against gastrointestinal diseases, providing essential support for physicians and patients alike.
